Detail of "30334-71-5"

Reference

Synthesis of bis[bis(acyloxy)propyl]phosphinate

Synthesis of bis[bis(acyloxy)propyl]phosphinate. Moschidis, Michael C. (Sancorin Lab., Athens 117 41, Greece). Chem. Phys.There are some reagents with their cas registry numbers 121-45-9 and 30334-71-5 are used in this study. Lipids, 39(3), 265-9 (English) 1986. CODEN: CPLIA4. ISSN: 0009-3084. DOCUMENT TYPE: Journal CA Section: 29 (Organometallic and Organometalloidal Compounds) (RCH2CHRCH2)2P(O)OH (R = palmitoyloxy) was prepd. by reaction of RCH2CHRCH2Br (I) with RCH2CHRCH2P(O)(OMe)2 (II) at 175°. II was prepd. by an Arbuzov reaction of I with P(OMe)3. .

Ceramide, a target for antiretroviral therapy

Ceramide, a target for antiretroviral therapy. Finnegan, Catherine M.Several substances are used for example 24696-26-2 and 30334-71-5 which are their cas registry numbers.; Rawat, Satinder S.; Puri, Anu; Wang, Ji Ming; Ruscetti, Francis W.; Blumenthal, Robert (Laboratories of Experimental and Computational Biology, National Institutes of Health, Frederick, MD 21702, USA). Proceedings of the National Academy of Sciences of the United States of America, 101(43), 15452-15457 (English) 2004 National Academy of Sciences. CODEN: PNASA6. ISSN: 0027-8424. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Studies of ceramide metab. and function in a wide range of biol. processes have revealed a role for this lipid in regulating key cellular responses. Our research on the role of sphingolipids in HIV entry has led to the hypothesis that modulation of ceramide levels in target cells affects their susceptibility to HIV infection by rearranging HIV receptors. Cellular ceramide levels were modulated by application of pharmacol. agents such as N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), by treatment with sphingomyelinase (Smase), or by exogenous addn. of long-chain ceramide, and detd. after metabolic incorporation of [3H]sphingosine. Infectivity assays were performed by using a HeLa-derived indicator cell line, TZM-bl, CD4+ lymphocytes, and monocytes. We obsd. a dose-dependent inhibition by 4-HPR of infection of TZM-bl cells by a broad range of HIV-1 isolates at low micromolar concns. with an IC50 of <1 mM for most isolates tested. Nearly complete inhibition was seen at 5 mM, a dose that enhanced ceramide levels by 50-100%, yet was nontoxic to the cells. Treating cells with other pharmacol. agents that enhanced ceramide levels, with Smase, or exogenous addn. of long-chain ceramide also resulted in inhibition of HIV-1 infection. Enhancing ceramide levels in CD4+ lymphocytes and in monocyte-derived macrophages with 4-HPR or Smase significantly reduced infectivity without toxicity. The minimal toxicity of normal cells exposed to 4-HPR should make the drug exceedingly suitable as an anti-HIV therapeutic. .